Bruker (BRKR)
(Delayed Data from NSDQ)
$80.97 USD
+0.38 (0.47%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $80.94 -0.03 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$80.97 USD
+0.38 (0.47%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $80.94 -0.03 (-0.04%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth B Momentum C VGM
Zacks News
Earnings Preview: Bruker (BRKR) Q1 Earnings Expected to Decline
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bruker (BRKR) Introduces Magnet Technology for NMR Adoption
by Zacks Equity Research
Bruker's (BRKR) latest novel technology facilitates the widespread application of NMR in academic basic and clinical research.
Bruker Corporation (BRKR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Bruker Corporation (BRKR) outperforms the industry due to its strengthening portfolio and robust quarterly results.
Why Is Bruker (BRKR) Up 15.7% Since Last Earnings Report?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bruker (BRKR) Up 20.7% Since Last Earnings: What's Driving It?
by Zacks Equity Research
Investors are upbeat about Bruker (BRKR) led by strong NANO group prospects and strong guidance.
Bruker (BRKR) Announces Advanced timsTOF Solutions at US HUPO
by Zacks Equity Research
Bruker (BRKR) advances CCS-Enabled 4D-Proteomics timsTOF solutions for immunopeptidomes and glycoproteomics at the US HUPO 2024.
Here's Why Investors Should Retain Bruker (BRKR) Stock Now
by Zacks Equity Research
The strength of the BSI BioSpin and CALID groups bodes well for Bruker (BRKR).
Bruker (BRKR) Inks Definitive Agreement to Acquire ELITechGroup
by Zacks Equity Research
Bruker (BRKR) announces a share purchase agreement to acquire the molecular diagnostics innovator ELITechGroup.
Bruker's (BRKR) New Launches Drive Growth Amid FX Woes
by Zacks Equity Research
Bruker's (BRKR) revenues continue to be driven by the strength of end markets, including academic and government, and industrial.
Zacks Industry Outlook Highlights Mettler-Toledo and Bruker
by Zacks Equity Research
Mettler-Toledo and Bruker have been highlighted in this Industry Outlook article.
2 Instruments Stocks to Buy From a Prospering Industry
by Aniruddha Ganguly
The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD) and Bruker (BRKR) are gaining from strong life science, pharmaceutical and academic end-market demand despite the challenging macroeconomic environment.
Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Strength in BioSpin and CALID groups contributes to Bruker's (BRKR) Q4 revenues.
Bruker (BRKR) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Bruker (BRKR) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Bruker (BRKR) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 7.69% and 2.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Trade Desk (TTD) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
The Trade Desk's (TTD) fourth-quarter 2023 performance is likely to have benefited from the growing CTV momentum and expanding partner base in the United States.
DoorDash (DASH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
DoorDash's (DASH) fourth-quarter 2023 results are likely to benefit from strong total orders and Marketplace GOV.
Why Bruker (BRKR) Might Surprise This Earnings Season
by Zacks Equity Research
Bruker (BRKR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Shopify (SHOP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Shopify's (SHOP) fourth-quarter 2023 performance is expected to have benefited from the growing adoption of merchant-friendly solutions despite the challenging macro environment.
IPG Photonics (IPGP) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
IPG Photonics' (IPGP) fourth-quarter 2023 results are likely to suffer from weakness in cutting and marking applications.
Qualys (QLYS) Surpasses Q4 Earnings Estimates
by Zacks Equity Research
Qualys (QLYS) delivered earnings and revenue surprises of 12% and 0.08%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout
by Zacks Equity Research
Trinity Biotech's (TRIB) focus on CGM as an initial step, utilizing a device with regulatory approval, provides a de-risked entry point in the wearable biosensor technology space.
Insulet (PODD) Gains From Product Innovation, Global Expansion
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.
Bruker (BRKR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Bruker (BRKR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bruker (BRKR) to Advance in Lab Automation With New Buyout
by Zacks Equity Research
This strategic move positions Bruker (BRKR) to further strengthen its Project Accelerate 2.0 initiative, focusing on "Assays, Software, and Aftermarket."